Clinical Trials Browser

Phase 1/2 × Not yet recruiting × Gemcitabine × Clear all

NCT06694454 2026-03-18

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Not yet recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07444541 2026-03-03

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07064863 2025-07-17

BCG-TIME

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Phase 1/2 Not yet recruiting

Gastrointestinal

Pancreatic Cancer Resectable

NCT06662669 2024-10-29

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06513455 2024-07-22

Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06370754 2024-04-17

FD-IMPACT

Phase 1/2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05898256 2023-06-12

Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 1/2 Not yet recruiting

Nasopharyngeal Carcinoma